← Back to Search

Non-Opioid Pain Medication for Postoperative Pain (OSPREy Trial)

Phase 4
Waitlist Available
Led By Evan Kharasch, MD
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-65 years Undergoing general anesthesia and moderately painful ambulatory surgery with anticipated postop stay of < 24 hours
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 hours
Awards & highlights

OSPREy Trial Summary

This trial is testing a new, non-opioid pain medication to see if it can help reduce pain after surgery while also reducing the amount of opioids consumed.

Who is the study for?
This trial is for adults aged 18-65 who are having outpatient surgery expected to cause moderate pain and require less than a day's hospital stay. They must understand and agree to the study terms. It's not for those with liver/kidney disease, pregnant/nursing women, or anyone using opioids daily.Check my eligibility
What is being tested?
The OSPREy-Outpatient Surgery Pain Relief Enhancement trial aims to refine pain management after surgery, reduce opioid use post-surgery, minimize side effects from opioids, and cut down on prescriptions that could lead to misuse.See study design
What are the potential side effects?
Opioids like Morphine, Sufentanil, Methadone, Fentanyl, and Hydromorphone can cause nausea, vomiting, constipation, drowsiness or sedation. There may also be risks of dependency or withdrawal symptoms.

OSPREy Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are between 18 and 65 years old and will have surgery with general anesthesia. Your surgery will be moderately painful, and you are expected to go home within 24 hours after the surgery.

OSPREy Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total 30 day post-discharge home opioid use (number of tablets)
Secondary outcome measures
Total 7d post-discharge home opioid use
Total PACU opioid administration
Total hospital non-methadone opioid administration
+1 more

OSPREy Trial Design

2Treatment groups
Active Control
Group I: IV methadoneActive Control1 Intervention
Intraoperative and post-operative IV methadone
Group II: IV fentanyl, sufentanil, morphine or hydromorphoneActive Control4 Interventions
Intraoperative and post-operative IV fentanyl, morphine or hydromorphone at anesthesia provider discretion

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,383 Previous Clinical Trials
3,426,704 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,492 Previous Clinical Trials
2,622,149 Total Patients Enrolled
Evan Kharasch, MDPrincipal InvestigatorDuke University

Media Library

IV methadone Clinical Trial Eligibility Overview. Trial Name: NCT03726268 — Phase 4
Opioid Use Disorder Research Study Groups: IV methadone, IV fentanyl, sufentanil, morphine or hydromorphone
Opioid Use Disorder Clinical Trial 2023: IV methadone Highlights & Side Effects. Trial Name: NCT03726268 — Phase 4
IV methadone 2023 Treatment Timeline for Medical Study. Trial Name: NCT03726268 — Phase 4
~140 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top